Literature DB >> 23888939

Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis.

Liang Rongrui, Huang Na, Li Zongfang, Ji Fanpu, Jiang Shiwen1.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection were known to be risk factors for HCC, they were suspected to promote its development by eliciting epigenetic changes. However, the precise gene targets and underlying mechanisms have not been elucidated. Epigenetic regulation of gene expression has emerged as a fundamental aspect of cancer development and progression. The molecular mechanisms of carcinogenesis in hepatocellular carcinoma involve a complex interplay of both genetic and epigenetic factors. DNA methylation, post-translational modifications of histone proteins, chromatin remodeling, and noncoding RNAs are four major types of mechanistic layers in the field of epigenetics. HBV infection could affect methylation on p16(INK4A), GSTP1, CDH1(E-cadherin), RASSF1A, p21(WAF1/CIP1) genes, which may play important roles in the development of HCC. HCV infection was related to aberrant methylation on SOCS-1, Gadd45β, MGMT, STAT1 and APC. Other epigenetic alterations included histone proteins, chromatin remodeling, and noncoding RNAs were described in literature. Uncovering the epigenetic alterations of HBV/HCV-induced HCC carcinogenesis could highlight a new strategy for deciphering the mechanism of HCC tumorigenesis and development, as well as a potential diagnostic advantage.

Entities:  

Mesh:

Year:  2014        PMID: 23888939     DOI: 10.2174/13816128113199990533

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  30 in total

1.  DNA methyltransferase DNMT3A associates with viral proteins and impacts HSV-1 infection.

Authors:  Daniell L Rowles; Yuan-Chin Tsai; Todd M Greco; Aaron E Lin; Minghao Li; Justin Yeh; Ileana M Cristea
Journal:  Proteomics       Date:  2015-05-07       Impact factor: 3.984

Review 2.  Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Yongjun Tian; Jing-hsiung James Ou
Journal:  Virol Sin       Date:  2015-04-07       Impact factor: 4.327

3.  DNA methyltransferase 1, 3a, and 3b expression in hepatitis C associated human hepatocellular carcinoma and their clinicopathological association.

Authors:  Nadir Naveed Siddiqui; Ahtesham Ul Haq; Owais Ali Siddiqui; Rizma Khan
Journal:  Tumour Biol       Date:  2016-02-05

Review 4.  Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis.

Authors:  Mirko Tarocchi; Simone Polvani; Giada Marroncini; Andrea Galli
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 5.  Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression.

Authors:  Concetta Panebianco; Chiara Saracino; Valerio Pazienza
Journal:  Tumour Biol       Date:  2014-05-16

6.  Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703.

Authors:  Baoqiang Wu; Yong Jiang; Feng Zhu; Donglin Sun; Hongjun Huang
Journal:  Oncol Lett       Date:  2016-02-18       Impact factor: 2.967

Review 7.  Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update.

Authors:  Gulsum Ozlem Elpek
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

8.  Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels.

Authors:  Wan-Ju Xu; Bao-Li Guo; Yu-Gang Han; Lei Shi; Wan-Shan Ma
Journal:  Tumour Biol       Date:  2014-09-12

9.  Circular RNA circRHOBTB3 is downregulated in hepatocellular carcinoma and suppresses cell proliferation by inhibiting miR-18a maturation.

Authors:  Gang Hu; Shusen Zhai; Sheng Yu; Zhen Huang; Ran Gao
Journal:  Infect Agent Cancer       Date:  2021-06-29       Impact factor: 2.965

10.  The Correlation Relationship between P14ARF Gene DNA Methylation and Primary Liver Cancer.

Authors:  Hui Zhang; Wanpin Nie; Feizhou Huang
Journal:  Med Sci Monit       Date:  2015-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.